Buffalo-based Pop Biotechnologies pulls in $3 million investment and other tech headlines

Published July 30, 2020


Buffalo Business First reports on the progress of two UB-affiliated companies. UB spinoff POP Biotechnologies has announced a $3 million investment and formation of a joint venture with Eubiologics for the development of an RSV vaccine and other vaccine candidates. Jonathan Lovell, associate professor of biomedical engineering, is co-founder of the company.

Additionally, Garwood Medical Devices, a UB partner company, was named as one of the top 10 medical device companies to watch in 2020 by Qualio, a software provider for medical device and pharmaceutical companies. Garwood's products include a method of controlling biofilm infections on implants, based on work done in the labs of UB engineering and medical researcher Mark Ehrensberger and UB medical researcher Anthony Campagnari, a SUNY Distinguished Professor. Garwood has space in UB buildings and has also leveraged various UB resources, including UB’s Buffalo Institute for Genomics and Data Analytics (BIG).

The story is available to subscribers here.